In short
Ecopipam Hydrochloride is an investigational drug being studied in clinical trials for its potential in treating Tourette's Disorder and its effects on cardiac repolarization. These trials aim to assess the efficacy, safety, and tolerability of Ecopipam in various patient populations, including children, adolescents, and adults. The studies also evaluate the drug's impact on heart function, providing crucial information for its development as a potential treatment option.
At a glance
- Drug Name
- Ecopipam Hydrochloride
- Primary Condition Studied
- Tourette's Disorder
- Secondary Study Focus
- Effects on cardiac repolarization (QT/QTc interval)
- Study Populations
- Children, adolescents, and adults with Tourette's Disorder; Healthy adult subjects
- Main Efficacy Measure
- Yale Global Tic Severity Scale (YGTSS)
- Study Designs
- Double-blind, placebo-controlled, randomized withdrawal; Thorough QT/QTc study
- Dosages Studied
- 1.8 mg/kg/day (therapeutic); 200 mg and 600 mg (for cardiac safety study)
- Key Safety Assessments
- Cardiac effects, adverse events, pharmacokinetics
What is Ecopipam Hydrochloride?
Ecopipam Hydrochloride, also known as EBS-101, is a new medication being studied for the treatment of Tourette's Disorder. Tourette's Disorder is a neurological condition characterized by repetitive, involuntary movements and vocalizations called tics. These tics can range from mild to severe and can significantly impact a person's quality of life.
How Does Ecopipam Work?
Ecopipam is classified as a selective dopamine D1 and D5 receptor antagonist. This means it works by blocking specific receptors in the brain that are involved in the transmission of dopamine, a neurotransmitter associated with movement control and reward. By targeting these specific receptors, Ecopipam may help reduce the frequency and severity of tics in people with Tourette's Disorder.
Treating Tourette's Disorder
Ecopipam is being investigated as a potential treatment for Tourette's Disorder in children, adolescents, and adults. The medication is administered as oral tablets, which are taken daily in the evening. The dosage is typically calculated based on the patient's body weight, with a target dose of 1.8 mg/kg/day of Ecopipam (equivalent to 2 mg/kg/day of Ecopipam Hydrochloride).
Current Clinical Trials
A Phase 3 clinical trial is currently underway to evaluate the effectiveness and safety of Ecopipam in treating Tourette's Disorder. This study includes:
- Open-label period: All participants receive Ecopipam for 12 weeks to determine if they respond to the treatment.
- Randomized withdrawal period: Participants who respond well to Ecopipam are randomly assigned to either continue the medication or switch to a placebo for 12 weeks.
The main goal of this study is to assess whether Ecopipam can maintain its effectiveness over time and to further evaluate its safety profile.
Safety Studies
In addition to evaluating Ecopipam's effectiveness in treating Tourette's Disorder, researchers are conducting thorough safety studies. One such study is specifically designed to assess the medication's effects on heart rhythm. This type of study, known as a "Thorough QT/QTc Study," is important because some medications can affect the heart's electrical activity, potentially leading to serious side effects.
The heart rhythm study involves:
- Testing both therapeutic (200 mg) and supratherapeutic (600 mg) doses of Ecopipam
- Comparing Ecopipam's effects to those of a placebo and a known heart rhythm-affecting drug (moxifloxacin)
- Monitoring participants' heart activity through ECGs (electrocardiograms) for up to 48 hours after taking the medication
- Analyzing blood samples to understand how the body processes Ecopipam
This comprehensive safety evaluation will help researchers better understand Ecopipam's potential risks and ensure its safe use in patients with Tourette's Disorder.
Potential Side Effects
As with any medication, Ecopipam may cause side effects. The ongoing clinical trials are designed to identify and assess these potential side effects. Some areas being closely monitored include:
- Changes in heart rate and rhythm
- Effects on blood pressure
- Impacts on other vital signs
- Any unexpected adverse events
It's important to note that the full range of potential side effects is still being studied, and more information will become available as the clinical trials progress.